Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? ; volume:81 ; number:16 ; day:27 ; month:10 ; year:2021 ; pages:1859-1879 ; date:11.2021
Drugs ; 81, Heft 16 (27.10.2021), 1859-1879, 11.2021
- Urheber
-
Mysler, Eduardo
Azevedo, Valderilio Feijó
Danese, Silvio
Alvarez, Daniel
Iikuni, Noriko
Ingram, Beverly
Mueller, Markus
Peyrin-Biroulet, Laurent
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-021-01610-1
- URN
-
urn:nbn:de:101:1-2022012208354097457811
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mysler, Eduardo
- Azevedo, Valderilio Feijó
- Danese, Silvio
- Alvarez, Daniel
- Iikuni, Noriko
- Ingram, Beverly
- Mueller, Markus
- Peyrin-Biroulet, Laurent
- SpringerLink (Online service)
Ähnliche Objekte (12)
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Current status and considerations on biosimilar in China
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Current status and considerations on biosimilar in China
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Current status and considerations on biosimilar in China
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
MYL-1402O: A Bevacizumab Biosimilar
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar